Preclinical evaluation of radiolabeled DOTA-derivatized cyclic minigastrin analogs for targeting cholecystokinin receptor expressing malignancies

Molecular Imaging and Biology

Volumn 14, Issue 3, 2012, Pages 366-375

  Von Guggenberg, Elisabeth ^a   Rangger, Christine ^a   Sosabowski, Jane ^b   Laverman, Peter ^c   Reubi, Jean Claude ^d   Virgolini, Irene Johanna ^a   Decristoforo, Clemens ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF BERN   (Switzerland)

Author keywords

Cholecystokinin receptors; Medullary thyroid carcinoma; Molecular imaging; Neuroendocrine tumors; Peptides; Radionuclides; Receptor targeting; Targeted therapy

Indexed keywords

CHOLECYSTOKININ B RECEPTOR; GALLIUM TETRAXETAN CYCLO(GAMMA DEXTRO GLUTAMYLALANYLTYROSINE DEXTRO LYSINE)TRYPTOPHANYLMETHIONYLASPARTYLPHENYLALANINAMIDE GA 68; GALLIUM TETRAXETAN CYCLO(GAMMA DEXTRO GLUTAMYLALANYLTYROSINE DEXTRO LYSINE)TRYPTOPHANYLNORLEUCYLASPARTYLPHENYLALANINAMIDE GA 68; INDIUM TETRAXETAN CYCLO(GAMMA DEXTRO GLUTAMYLALANYLTYROSINE DEXTRO LYSINE)TRYPTOPHANYLMETHIONYLASPARTYLPHENYLALANINAMIDE IN 111; INDIUM TETRAXETAN CYCLO(GAMMA DEXTRO GLUTAMYLALANYLTYROSINE DEXTRO LYSINE)TRYPTOPHANYLNORLEUCYLASPARTYLPHENYLALANINAMIDE IN 111; TRACER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SCINTISCANNING; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN TISSUE; INTERNALIZATION; ISOTOPE LABELING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TARGETING; RADIOISOTOPE DISTRIBUTION; RECEPTOR AFFINITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; FEMALE; GALLIUM RADIOISOTOPES; GASTRINS; HETEROCYCLIC COMPOUNDS, 1-RING; INDIUM RADIOISOTOPES; MICE; MICE, INBRED BALB C; MICE, NUDE; MICE, SCID; RECEPTORS, CHOLECYSTOKININ; THYROID NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

ANIMALIA;

EID: 84861482832     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-011-0506-2     Document Type: Article

References (44)

1. Kwekkeboom DJ, de Herder WW, van Eijck CH, Kam BL, van Essen M, Teunissen JJ, Krenning EP (2010) Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 40:78-88
2. Virgolini IJ, Gabriel M, von Guggenberg E, Putzer D, Kendler D, Decristoforo C (2009) Role of radiopharmaceuticals in the diagnosis and treatment of neuroendocrine tumours. Eur J Cancer 45:S274-S291
3. Reubi JC (2007) Targeting CCK receptors in human cancers. Curr Top Med Chem 7:1239-1242
4. Behe M, Behr TM (2002) Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies. Biopolymers 66:399-418
5. Behr TM, Gotthardt M, Barth A, Behe M (2001) Imaging tumors with peptide-based radioligands. Q J Nucl Med 45:189-200 (Pubitemid 32640394)
6. Gotthardt M, Béhé MP, Beuter D, Battmann A, Bauhofer A, Schurrat T, Schipper M, Pollum H, Oyen WJ, Behr TM (2006) Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 33:1273-1279 (Pubitemid 44630781)
7. Gotthardt M, Béhé MP, Grass J, Bauhofer A, Rinke A, Schipper ML, Kalinowski M, Arnold R, Oyen WJ, Behr TM (2006) Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours. Endocr Relat Cancer 13:1203-1211 (Pubitemid 46212574)
8. 111In-labelled minigastrin. Eur J Nucl Med Mol Imaging 35:386-392
9. Béhé M, Becker W, Gotthardt M, Angerstein C, Behr TM (2003) Improved kinetic stability of DTPA- dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives. Eur J Nucl Med Mol Imaging 30:1140-1146 (Pubitemid 36988226)
10. 99mTc-Labeling, in vitro and in vivo evaluation of HYNIC and (Nα-His)-acetic acid modified [D-Glu1]-Minigastrin. Bioconjug Chem 15:864-871
11. 99mTc-labeled minigastrin analogs. J Nucl Med 46:1727-1736
12. Melis M, Krenning EP, Bernard BF, de Visser M, Rolleman E, de Jong M (2007) Renal uptake and retention of radiolabeled somatostatin; bombesin; neurotensin; minigastrin and CCK analogs: species and gender differences. Nucl Med Biol 34:633-641 (Pubitemid 47248283)
13. Béhé M, Kluge G, Becker W, Gotthardt M, Behr TM (2005) Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneys. J Nucl Med 46:1012-1015 (Pubitemid 43733517)
14. Behe M, Reubi J, Nock B, Mäcke H, Breeman WAP, Bernard HF, Behr TM, De Jong M (2005) Evaluation of a DOTA-minigastrin derivative for therapy and diagnosis for CCK-2 receptor positive tumours. Eur J Nucl Med Mol Imaging 32:S78
15. Helbok A, Decristoforo C, Behe M, Rangger C, von Guggenberg E (2009) Preclinical evaluation of In-111 and Ga-68 labelled minigastrin analogues for CCK-2 receptor imaging. Current Radiopharm 2:304-310
16. 99mTc-labelled HYNIC-minigastrin with reduced kidney uptake for targeting of CCK-2 receptor-positive tumours. Eur J Nucl Med Mol Imaging 34:1209-1218
17. Nikolopoulou A, Nock BA, Petrou C, Ketani E, Cordopatis P, Maina T (2006) In vivo targeting of CCK-2/Gastrin-R and reduction of renal accumulation with truncated [99mTc]Demogastrin 4-6. In: Mazzi U, Giron MC, Nadali A, Rossin R (eds) Technetium, Rhenium and Other Materials in Chemistry and Nuclear Medicine 7. SGEditotoriali, Padova, pp 325-326
18. 99mTc- EDDA/HYNIC-DGlu-octagastrin for scintigraphy of medullary thyroid carcinoma. Cancer Biother Radiopharm 22:613-628
19. Good S, Walter MA, Waser B, Wang X, Müller-Brand J, Béhé MP, Reubi JC, Maecke HR (2008) Macrocyclic chelator-coupled gastrin-based radiopharmaceuticals for targeting of gastrin receptor-expressing tumours. Eur J Nucl Med Mol Imaging 35:1868-1877
20. Stone SR, Giragossian C, Mierke DF, Jackson GE (2007) Further evidence for a C-terminal structural motif in CCK2 receptor active peptide hormones. Peptides 28:2211-2222 (Pubitemid 47600422)
21. von Guggenberg E, Sallegger W, Helbok A, Ocak M, King R, Mather SJ, Decristoforo C (2009) Cyclic Minigastrin analogues for gastrin receptor scintography with Technitium-99 m: preclinical evaluation. J Med Chem 52:4786-4793
22. Svoboda M, Dupuche MH, Lambert M, Bui D, Christophe J (1990) Internalization-sequestration and degradation of cholecystokinin (CCK) in tumoral rat pancreatic AR 4-2 J cells. Biochim Biophys Acta 1055:207-216
23. Reubi JC, Schaer JC, Waser B (1997) Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res 57:1377-1386 (Pubitemid 27152565)
24. 177Lu-DOTA-cyclogastrin: stability assessment and evaluation in vitro. J Label Compd Radiopharm 52:S514
25. de Visser M, Verwijnen SM, de Jong M (2008) Update: improvement strategies for peptide receptor scintigraphy and radionuclide therapy. Cancer Biother Radiopharm 23:137-157 (Pubitemid 351649281)
26. Reubi JC, Maecke HR (2008) Peptide-based probes for cancer imaging. J Nucl Med 49:1735-1738
27. 111In-labeled CCK-2/gastrin receptor-specific peptides in rats. Anticancer Res 27:907-912
28. 90Y-DOTATOC. Eur J Nucl Med 26:877-886
29. 111In-labelled DOTA-RGD peptides for imaging of alphavbeta3 integrin expression. Eur J Nucl Med Mol Imaging 35:1507-1515
30. Charpentier B, Pelaprat D, Durieux C, Dor A, Reibaud M, Blanchard JC, Roques BP (1988) Cyclic cholecystokinin analogs with high selectivity for central receptors. Proc Natl Acad Sci USA 85:1968-1972 (Pubitemid 24315806)
31. 111In-labelled minigastrin dimer. Q J Nucl Med Mol Imaging 52:S13
32. Akgün E, Körner M, Gao F, Harikumar KG, Waser B, Reubi JC, Portoghese PS, Miller LJ (2009) Synthesis and in vitro characterization of radioiodinatable benzodiazepines selective for type 1 and type 2 cholecystokinin receptors. J Med Chem 52:2138-2147
33. 111In-DOTA-MG. In: Mazzi U, Giron MC, Nadali A, Rossin R (eds) Technetium, rhenium and other materials in Chemistry and Nuclear Medicine 7. SGEditotoriali, Padova, pp 231-232
34. Mather SJ, McKenzie AJ, Sosabowski JK, Morris TM, Ellison D, Watson SA (2007) Selection of radiolabeled gastrin analogs for peptide receptor-targeted radionuclide therapy. J Nucl Med 48:615-622 (Pubitemid 47571419)
35. 11 in [99mTc] demogastrin 2: effects on CCK-2/gastrin-R-interaction. In: Mazzi U, Giron MC, Nadali A, Rossin R (eds) Technetium, rhenium and other materials in Chemistry and Nuclear Medicine 7. SGEditotoriali, Padova, pp 323-324
36. Sosabowski JK, Lee M, Dekker BA, Simmons BP, Singh S, Beresford H, Hagan SA, McKenzie AJ, Mather SJ, Watson SA (2007) Formulation development and manufacturing of a gastrin/CCK-2 receptor targeting peptide as an intermediate drug product for a clinical imaging study. Eur J Pharm Sci 31:102-111 (Pubitemid 46660579)
37. Werle M, Bernkop-Schnürch A (2006) Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids 30:351-367 (Pubitemid 43886897)
38. Breeman WA, Froberg AC, de Blois E, van Gameren A, Melis M, de Jong M, Maina T, Nock BA, Erion JL, Macke HR, Krenning EP (2008) Optimised labeling, preclinical and initial clinical aspects of CCK-2 receptor-targeting with 3 radiolabeled peptides. Nucl Med Biol 35:839-849
39. Ocak M, Helbok A, Rangger C, Peitl PK, Nock BA, Morelli G, Eek A, Sosabowski JK, Breeman WA, Reubi JC, Decristoforo C (2011) Comparison of biological stability and metabolism of CCK2 receptor targeting peptides, a collaborative project under COST BM0607. Eur J Nucl Med Mol Imaging (in press)
40. Reubi JC, Schär JC, Waser B, Wenger S, Heppeler A, Schmitt JS, Mäcke HR (2000) Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 27:273-282 (Pubitemid 30167697)
41. Ginj M, Chen J, Walter MA, Eltschinger V, Reubi JC, Maecke HR (2005) Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy. Clin Cancer Res 11:1136-1145 (Pubitemid 40175763)
42. 68Ga-DOTA- Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 48:508-518
43. Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, Maecke H (2007) Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 34:982-993
44. de Jong M, Breeman WA, Bernard BF, van Gameren A, de Bruin E, Bakker WH, van der Pluijm ME, Visser TJ, Mäcke HR, Krenning EP (1999) Tumour uptake of the radiolabelled somatostatin analogue [DOTA0, TYR3]octreotide is dependent on the peptide amount. Eur J Nucl Med 26:693-698